Study search
Go straight to the source
Search PubMed, Europe PMC and ClinicalTrials.gov from one box. Results come from the indexes themselves, newest first, each linked to its original record.
Amiravo's reviewed summary: Pemvidutide research reference →
13 records · open this search in PubMed
- PubMedReviewEfficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.Cureus · 2026 Jun
- PubMedMeta-AnalysisEfficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026 Jun
- PubMedGlucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.Addictive behaviors reports · 2026 Jun
- PubMedSystemic Pharmacokinetic Principles of Therapeutic Peptides.Clinical pharmacokinetics · 2026 Apr
- PubMedThe dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.Lancet (London, England) · 2025 Dec 6
- PubMedRandomized Controlled TrialClinical Trial, Phase IIMulticenter StudySafety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.Lancet (London, England) · 2025 Dec 6
- PubMedMuscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions.Journal of cachexia, sarcopenia and muscle · 2025 Dec
- PubMedSafety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.JHEP reports : innovation in hepatology · 2025 Nov
- PubMedReviewReview: Special Issue: Real-world evidence on the use of GLP1 receptor agonists: Emerging concepts in obesity management: focus on glucagon receptor agonist combinations.Drugs in context · 2025
- PubMedReviewMultifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides · 2025 May
- PubMedReviewCurrent priorities in research on metabolic-associated fatty liver disease based on the results of EASL - 2024.Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego · 2025
- PubMedRandomized Controlled TrialMulticenter StudyResearch Support, Non-U.S. Gov'tEffect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.Journal of hepatology · 2025 Jan
- PubMedReviewApproved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article.Indian journal of endocrinology and metabolism · 2024 Sep-Oct
Queries go directly from your browser to NCBI, EMBL-EBI and ClinicalTrials.gov; Amiravo does not store them. Study-type labels come from the indexes and can be wrong. A record's presence says nothing about whether a compound works or is safe. PubMed data via NCBI E-utilities; see NCBI policies.